Press Releases Archives - Page 29 of 103 - Lupin

BSE 2303.70 NSE 2305.20

indian flag icon

India

USA

great-britain flag icon

UK

south-africa flag icon

South Africa

australia flag icon

Australia

philippines flag icon

Philippines

germany flag icon

Germany

netherlands flag icon

Netherlands

mexico flag icon

Mexico

brazil flag icon

Brazil

canada flag icon

Canada

Switzerland flag icon

Switzerland

BSE 2303.70 NSE 2305.20

Lupin Receives Tentative Approval from U.S. FDA for Doxycycline Capsules

November 8, 2022

Lupin Receives Tentative Approval from U.S. FDA for Drospirenone Tablets

November 4, 2022

Lupin Launches Paliperidone Extended-Release Tablets in the United States

October 20, 2022

Lupin Signs Agreement to Acquire Two Inhalation Brands from Sunovion

October 20, 2022

Lupin Partners with Global Agencies to Increase Patient Access to Tuberculosis Prevention Treatment

October 7, 2022

Lupin Appoints Dr. Shahin Fesharaki as Global Chief Scientific Officer

October 7, 2022

Lupin Receives Approval from U.S. FDA for Darunavir Tablets

October 4, 2022

Lupin Life announces association with Vikram Vedha as official energy partner with its Be One health and wellness supplement

October 1, 2022

Lupin gets EIR from US FDA for its Ankleshwar Manufacturing Facility

October 1, 2022

Lupin Receives Approval from U.S. FDA for Mirabegron Extended-Release Tablets

September 29, 2022

1 2 … 28 29 30 … 102 103

Search

Hit enter to search or ESC to close